Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
(1) Objective (Cohorts A+C): To evaluate the Overall Response Rate (ORR) to pembrolizumab as 2L+ monotherapy in subjects with PD-L1 strong (+) centrally confirmed mTNBC, based on RECIST 1.1 as assessed by the central imaging vendor. (2) Objective (Cohort A): To evaluate the ORR to pembrolizumab as 2L+ monotherapy for PD-L1 (+) centrally confirmed mTNBC, based on RECIST 1.1 as assessed by the central imaging vendor. (3) Objective (Cohort A): To evaluate the ORR to pembrolizumab as 2L+ monotherapy for centrally confirmed mTNBC independent of PD-L1 status (all comers), based on RECIST 1.1 as assessed by the central imaging vendor. (4) Objective (Cohorts A-C): To determine the safety and tolerability of pembrolizumab monotherapy for mTNBC across cohorts and by PD-L1 status within the line of treatment for mTNBC.
Critère d'inclusion
- Triple Negative Breast Cancer